Complete formulations income elevated by 4.6% to Rs 7,646 crore, whereas complete API gross sales elevated by virtually 13% to Rs 1,208 crore. Photograph courtesy: Particular Association
Aurobindo Pharma’s consolidated internet revenue for the March quarter rose 2% to Rs 921 crore in comparison with Rs 930 crore within the year-ago interval.
The Hyderabad-headquartered generic drug maker’s working income rose 5.6% to Rs 8,853 billion (Rs 8,382 billion) at the same time as its US formulations income fell from Rs 1.3 billion to Rs 3,543 billion year-on-year, primarily as a result of one-off gross sales declines. Revenues had been pushed by Europe and development markets. In Europe, Aurobindo Pharma posted a 30.2% improve in income to Rs 2,795 crore (Rs 2,147 crore). It accounted for over 24.7% of the rising market and reached Rs 986 crore (Rs 786 million).
Complete formulations income elevated by 4.6% to Rs 7,646 crore, whereas complete API gross sales elevated by virtually 13% to Rs 1,208 crore.
Ok. Nithyananda Reddy, Vice Chairman and Managing Director, mentioned, “We’re inspired by our outcomes for the quarter and the yr, which mirror the resilience of our enterprise mannequin and the energy of our broad product portfolio. Regular volumes, coupled with improved operational effectivity and disciplined execution, contributed positively to our outcomes.”
Internet revenue for FY26 was flat at Rs 3,503 crore (Rs 3,484 crore), whereas working income elevated by 6.1% to Rs 33,653 crore (Rs 31,724 crore). The corporate introduced that its European operations had gross sales of over 1 billion euros this yr.
